Indications for AVANDIA:
Adjunct to diet and exercise in type 2 diabetes. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis. Not for use with insulin.
≥18yrs: Give once daily or in two divided doses (AM & PM). Initially 4mg/day; may increase after 8–12 weeks; max 8mg/day.
<18yrs: not recommended.
Concomitant metformin in renal impairment. NYHA Class III or IV heart failure.
Congestive heart failure.
Symptomatic HF or acute coronary syndromes: not recommended. CHF: NYHA Class I or II: increased risk of cardiovascular events (monitor); discontinue or reduce dose if develops. Edema. Monitor for signs/symptoms of heart failure. Hepatic disease. Do not start therapy in active liver disease or if ALT >2.5xULN. Monitor transaminases at baseline, then periodically. If ALT is mildly elevated (≤2.5xULN), follow-up and monitor closely; discontinue if ALT >3xULN or jaundice occurs. Monitor fasting blood glucose and HbA1c levels periodically. Perform regular eye exams. Resumption of premenopausal ovulation in anovulatory patients may occur (may result in unintended pregnancy). Pregnancy. Nursing mothers.
Concomitant insulin: not recommended. Potentiated by other CYP2C8 inhibitors (eg, gemfibrozil). Antagonized by CYP2C8 inducers (eg, rifampin). Increased risk of hypoglycemia with concomitant other hypoglycemics; may need to reduce dose.
Upper respiratory tract infection, injury, headache, edema, weight gain, anemia, changes in serum lipids, macular edema (possible); also women: risk of fracture. See full labeling re: risk of myocardial ischemic events.
Tabs 2mg—60; 4mg—30